IL2 and vasculitis: Ten HCV individuals with refractory to conventional and/or rituximab therapy vasculitis received one course of IL-2 administered sq at 1.5 × 106 IU/day for 5 days followed by a 9-day rest period, with additional courses of 3 × 106 IU/day for 5 days at weeks 3, 6, and 9.